Understanding why some individuals with Down syndrome develop debilitating dementia while others with identical amyloid burden do not has long puzzled neurologists. A comprehensive review in Brain, Behavior, and Immunity now offers a reframing that could meaningfully alter therapeutic strategy: chronic neuroinflammation, not amyloid accumulation alone, appears to be the central engine driving Alzheimer's progression in this population.
The review synthesizes neuropathological, multi-omics, and cellular evidence to argue that immune dysregulation in Down syndrome begins prenatally — well before amyloid plaques or tau tangles appear — and persists across the entire lifespan. Trisomy 21 encodes an extra copy of the APP gene, guaranteeing near-universal amyloid pathology by midlife, yet symptomatic dementia follows in only a subset of adults, pointing to modulatory factors beyond plaque burden. The authors identify microglial hyperactivation, interferon-driven "interferonopathy" stemming from the chromosome 21-encoded interferon receptor gene cluster, oxidative redox imbalance, tauopathy, and cerebrovascular dysfunction as converging forces that collectively determine whether amyloid pathology tips into clinical dementia. Peripheral immune abnormalities — including thyroid disease, sleep apnea, and endocrine comorbidities — are shown to further amplify central neuroinflammation. Critically, preclinical models demonstrate that microglial activation and redox disruption precede synaptic loss, and that targeted interventions reversing these processes show functional benefit.
This reframing carries substantial implications for the broader Alzheimer's field, not just for the Down syndrome community. The amyloid hypothesis has dominated Alzheimer's research for decades, yet anti-amyloid therapies have shown limited efficacy in general populations. Down syndrome-associated Alzheimer's offers a uniquely tractable human model — genetically defined, with a known timeline — to test inflammation-targeting strategies. The review's greatest strength is its integration across biological scales, from prenatal microglial priming to peripheral immune crosstalk, suggesting that effective intervention may need to begin early and target multiple pathways simultaneously. As a review rather than original trial data, causality remains inferential, but the convergence of evidence across independent methodologies lends the argument genuine force. Anti-inflammatory and redox-targeting trials in this population deserve urgent prioritization.